Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase

Biochemical and Biophysical Research Communications

Volumn 400, Issue 3, 2010, Pages 374-378

  Pandey, Amit V ^a   Flück, Christa E ^a   Mullis, Primus E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adrenal hyperplasia; Antley Bixler syndrome; CPR; Heme oxygenase; NADPH P450 reductase; NADPH:ferrihemoprotein oxidoreductase; P450 reductase; POR

Indexed keywords

CYTOCHROME P450 REDUCTASE; HEME OXYGENASE 1; FLAVINE MONONUCLEOTIDE; HEME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ADRENAL HYPERPLASIA; ALLELE; ANTLEY BIXLER SYNDROME; ARTICLE; CATABOLISM; GENE MUTATION; HUMAN; P450 OXIDOREDUCTASE DEFICIENCY; PRIORITY JOURNAL; CONGENITAL ADRENAL HYPERPLASIA; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE;

ADRENAL HYPERPLASIA, CONGENITAL; ALLELES; FLAVIN MONONUCLEOTIDE; HEME; HEME OXYGENASE-1; HUMANS; MUTATION; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY;

EID: 77956907216     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.072     Document Type: Article

References (47)

1. Lu A.Y., Junk K.W., Coon M.J. Resolution of the cytochrome P-450-containing ω-hydroxylation system of liver microsomes into three components. J. Biol. Chem. 1969, 244:3714-3721.
2. Schacter B.A., Nelson E.B., Marver H.S., Masters B.S. Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J. Biol. Chem. 1972, 247:3601-3607.
3. Kikuchi G., Yoshida T., Noguchi M. Heme oxygenase and heme degradation. Biochem. Biophys. Res. Commun. 2005, 338:558-567.
4. Ilan Z., Ilan R., Cinti D.L. Evidence for a new physiological role of hepatic NADPH:ferricytochrome (P-450) oxidoreductase. Direct electron input to the microsomal fatty acid chain elongation system. J. Biol. Chem. 1981, 256:10066-10072.
5. Bligh H.F., Bartoszek A., Robson C.N., Hickson I.D., Kasper C.B., Beggs J.D., Wolf C.R. Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res. 1990, 50:7789-7792.
6. Bartoszek A., Wolf C.R. Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase. Biochem. Pharmacol. 1992, 43:1449-1457.
7. Kurzban G.P., Strobel H.W. Preparation and characterization of FAD-dependent NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1986, 261:7824-7830.
8. Masters B.S. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem. Biophys. Res. Commun. 2005, 338:507-519.
9. Vermilion J.L., Ballou D.P., Massey V., Coon M.J. Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1981, 256:266-277.
10. Iyanagi T., Mason H.S. Some properties of hepatic reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase. Biochemistry 1973, 12:2297-2308.
11. Flück C.E., Mullis P.E., Pandey A.V. Modeling of human P450 oxidoreductase structure by in silico mutagenesis and Md simulation. Mol. Cell. Endocrinol. 2009, 313:17-22.
12. Gutierrez A., Lian L.Y., Wolf C.R., Scrutton N.S., Roberts G.C. Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains. Biochemistry 2001, 40:1964-1975.
13. Munro A.W., Noble M.A., Robledo L., Daff S.N., Chapman S.K. Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 2001, 40:1956-1963.
14. Yoshida T., Kikuchi G. Purification and properties of heme oxygenase from rat liver microsomes. J. Biol. Chem. 1979, 254:4487-4491.
15. Tenhunen R., Marver H.S., Schmid R. Microsomal heme oxygenase characterization of the enzyme. J. Biol. Chem. 1969, 244:6388-6394.
16. Tenhunen R., Marver H.S., Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. USA 1968, 61:748-755.
17. Flück C.E., Tajima T., Pandey A.V., Arlt W., Okuhara K., Verge C.F., Jabs E.W., Mendonca B.B., Fujieda K., Miller W.L. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat. Genet. 2004, 36:228-230.
18. Huang N., Pandey A.V., Agrawal V., Reardon W., Lapunzina P.D., Mowat D., Jabs E.W., Van Vliet G., Sack J., Flück C.E., Miller W.L. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 2005, 76:729-749.
19. Pandey A.V., Kempna P., Hofer G., Mullis P.E., Flück C.E. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol. Endocrinol. 2007, 21:2579-2595.
20. Flück C.E., Pandey A.V., Huang N., Agrawal V., Miller W.L. P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia. Endocr. Dev. 2008, 13:67-81.
21. Flück C.E., Nicolo C., Pandey A.V. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam. Clin. Pharmacol. 2007, 21:399-410.
22. Miller W.L., Huang N., Pandey A.V., Flück C.E., Agrawal V. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann. NY Acad. Sci. 2005, 1061:100-108.
23. Miller W.L., Huang N., Flück C.E., Pandey A.V. P450 oxidoreductase deficiency. Lancet 2004, 364:1663.
24. Nicolo C., Flück C.E., Mullis P.E., Pandey A.V. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol. Cell. Endocrinol. 2010, 321:245-252.
25. Arlt W., Walker E.A., Draper N., Ivison H.E., Ride J.P., Hammer F., Chalder S.M., Borucka-Mankiewicz M., Hauffa B.P., Malunowicz E.M., Stewart P.M., Shackleton C.H. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004, 363:2128-2135.
26. Adachi M., Tachibana K., Asakura Y., Yamamoto T., Hanaki K., Oka A. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am. J. Med. Genet. 2004, 128A:333-339.
27. Fukami M., Horikawa R., Nagai T., Tanaka T., Naiki Y., Sato N., Okuyama T., Nakai H., Soneda S., Tachibana K., Matsuo N., Sato S., Homma K., Nishimura G., Hasegawa T., Ogata T. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metab. 2005, 90:414-426.
28. Hart S.N., Wang S., Nakamoto K., Wesselman C., Li Y., Zhong X.B. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genom. 2008, 18:11-24.
29. Huang N., Agrawal V., Giacomini K.M., Miller W.L. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. USA 2008, 105:1733-1738.
30. Sim S.C., Miller W.L., Zhong X.B., Arlt W., Ogata T., Ding X., Wolf C.R., Flück C.E., Pandey A.V., Henderson C.J., Porter T.D., Daly A.K., Nebert D.W., Ingelman-Sundberg M. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet. Genom. 2009, 19:565-566.
31. Homma K., Hasegawa T., Nagai T., Adachi M., Horikawa R., Fujiwara I., Tajima T., Takeda R., Fukami M., Ogata T. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J. Clin. Endocrinol. Metab. 2006, 91:2643-2649.
32. Fukami M., Hasegawa T., Horikawa R., Ohashi T., Nishimura G., Homma K., Ogata T. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr. Res. 2006, 59:276-280.
33. Adachi M., Asakura Y., Matsuo M., Yamamoto T., Hanaki K., Arlt W. POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am. J. Med. Genet. A 2006, 140:633-635.
34. Kranendonk M., Marohnic C.C., Panda S.P., Duarte M.P., Oliveira J.S., Masters B.S., Rueff J. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 2008, 475:93-99.
35. Agrawal V., Huang N., Miller W.L. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genom. 2008, 18:569-576.
36. Gomes A.M., Winter S., Klein K., Turpeinen M., Schaeffeler E., Schwab M., Zanger U.M. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009, 10:579-599.
37. Oneda B., Crettol S., Jaquenoud Sirot E., Bochud M., Ansermot N., Eap C.B. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet. Genom. 2009, 19:877-883.
38. Pandey A.V., Miller W.L. Regulation of 17, 20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J. Biol. Chem. 2005, 280:13265-13271.
39. Huber W.J., Marohnic C.C., Peters M., Alam J., Reed J.R., Masters B.S., Backes W.L. Measurement of membrane-bound human heme oxygenase-1 activity using a chemically defined assay system. Drug Metab. Dispos. 2009, 37:857-864.
40. McNally S.J., Ross J.A., James Garden O., Wigmore S.J. Optimization of the paired enzyme assay for heme oxygenase activity. Anal. Biochem. 2004, 332:398-400.
41. Pandey A.V., Joshi S.K., Tekwani B.L., Chauhan V.S. A colorimetric assay for heme in biological samples using 96-well plates. Anal. Biochem. 1999, 268:159-161.
42. Marohnic C.C., Panda S.P., McCammon K., Rueff J., Masters B.S., Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab. Dispos. 2010, 38:332-340.
43. Peterson R.E., Imperato-McGinley J., Gautier T., Shackleton C.H.L. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. New Engl. J. Med. 1985, 313:1182-1191.
44. Wang J., de Montellano P.R. The binding sites on human heme oxygenase-1 for cytochrome p450 reductase and biliverdin reductase. J. Biol. Chem. 2003, 278:20069-20076.
45. Higashimoto Y., Sakamoto H., Hayashi S., Sugishima M., Fukuyama K., Palmer G., Noguchi M. Involvement of NADPH in the interaction between heme oxygenase-1 and cytochrome P450 reductase. J. Biol. Chem. 2005, 280:729-737.
46. Miller W.L., Huang N., Agrawal V., Giacomini K.M. Genetic variation in human P450 oxidoreductase. Mol. Cell. Endocrinol. 2009, 300:180-184.
47. Pandey A.V. Biochemical analysis of mutations in P450 oxidoreductase. Biochem. Soc. Trans. 2006, 34:1186-1191.